Operating Expenses Summary of GenMont Biotech Incorporation

GenMont Biotech Incorporation's latest annual operating expenses in 2023 was 204.2 Million TWD , down -13.32% from previous year.
GenMont Biotech Incorporation's latest quarterly operating expenses in 2024 Q2 was 40.81 Million TWD , up 24.28% from previous quarter.
GenMont Biotech Incorporation reported a annual operating expenses of 196.53 Million TWD in annual operating expenses 2022, up 14.94% from previous year.
GenMont Biotech Incorporation reported a annual operating expenses of 170.98 Million TWD in annual operating expenses 2021, up 17.9% from previous year.
GenMont Biotech Incorporation reported a quarterly operating expenses of 40.81 Million TWD for 2024 Q2, up 24.28% from previous quarter.
GenMont Biotech Incorporation reported a quarterly operating expenses of 52.46 Million TWD for 2023 Q2, up 10.2% from previous quarter.

Annual Operating Expenses Chart of GenMont Biotech Incorporation (2023 - 2009)

Historical Annual Operating Expenses of GenMont Biotech Incorporation (2023 - 2009)

Year	Operating Expenses	Operating Expenses Growth
2023	204.2 Million TWD	-13.32%
2022	196.53 Million TWD	14.94%
2021	170.98 Million TWD	17.9%
2020	145.03 Million TWD	-5.17%
2019	152.93 Million TWD	-1.16%
2018	154.72 Million TWD	-47.55%
2017	294.99 Million TWD	-10.12%
2016	328.19 Million TWD	2.8%
2015	319.25 Million TWD	-19.73%
2014	397.7 Million TWD	153.11%
2013	157.13 Million TWD	-9.23%
2012	173.11 Million TWD	-16.94%
2011	208.4 Million TWD	-11.97%
2010	236.74 Million TWD	27.33%
2009	185.92 Million TWD	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q1	40.14 Million TWD	-1.78%
2024 Q2	40.81 Million TWD	24.28%
2023 Q2	52.46 Million TWD	10.2%
2023 Q3	50.89 Million TWD	-2.99%
2023 FY	170.34 Million TWD	-13.32%
2023 Q4	40.87 Million TWD	-19.68%
2023 Q1	47.61 Million TWD	-10.85%
2022 Q4	53.4 Million TWD	2.88%
2022 FY	196.53 Million TWD	14.94%
2022 Q3	51.91 Million TWD	6.42%
2022 Q2	48.78 Million TWD	14.95%
2022 Q1	42.43 Million TWD	-5.94%
2021 Q1	34.6 Million TWD	-21.96%
2021 FY	170.98 Million TWD	17.9%
2021 Q4	45.11 Million TWD	-2.66%
2021 Q3	46.34 Million TWD	3.18%
2021 Q2	44.91 Million TWD	29.81%
2020 Q1	34.76 Million TWD	8.21%
2020 Q2	32.29 Million TWD	-7.1%
2020 Q3	33.62 Million TWD	4.09%
2020 FY	145.03 Million TWD	-5.17%
2020 Q4	44.34 Million TWD	31.89%
2019 FY	152.93 Million TWD	-1.16%
2019 Q1	36.78 Million TWD	0.11%
2019 Q3	43.72 Million TWD	8.51%
2019 Q2	40.29 Million TWD	9.54%
2019 Q4	32.12 Million TWD	-26.52%
2018 Q1	66.54 Million TWD	-9.61%
2018 FY	154.72 Million TWD	-47.55%
2018 Q4	36.74 Million TWD	1.83%
2018 Q3	36.08 Million TWD	-23.15%
2018 Q2	46.95 Million TWD	-29.44%
2017 Q2	74.96 Million TWD	8.37%
2017 FY	294.99 Million TWD	-10.12%
2017 Q4	73.62 Million TWD	-4.67%
2017 Q3	77.23 Million TWD	3.03%
2017 Q1	69.17 Million TWD	-13.86%
2016 FY	328.19 Million TWD	2.8%
2016 Q4	80.3 Million TWD	-3.11%
2016 Q3	82.87 Million TWD	-1.75%
2016 Q2	84.35 Million TWD	4.58%
2016 Q1	80.65 Million TWD	4.48%
2015 FY	319.25 Million TWD	-19.73%
2015 Q1	79.37 Million TWD	-34.8%
2015 Q2	79.33 Million TWD	-0.05%
2015 Q3	83.34 Million TWD	5.05%
2015 Q4	77.19 Million TWD	-7.37%
2014 FY	397.7 Million TWD	153.11%
2014 Q3	104.31 Million TWD	5.75%
2014 Q1	73 Million TWD	36.98%
2014 Q4	121.74 Million TWD	16.71%
2014 Q2	98.64 Million TWD	35.11%
2013 Q4	53.29 Million TWD	69.73%
2013 FY	157.13 Million TWD	-9.23%
2013 Q2	39.12 Million TWD	17.46%
2013 Q1	33.3 Million TWD	-20.16%
2013 Q3	31.4 Million TWD	-19.74%
2012 Q4	41.72 Million TWD	1.02%
2012 Q2	49.59 Million TWD	21.24%
2012 Q1	40.9 Million TWD	-13.99%
2012 Q3	41.3 Million TWD	-16.72%
2012 FY	173.11 Million TWD	-16.94%
2011 Q2	53.72 Million TWD	-7.61%
2011 Q1	58.15 Million TWD	-20.45%
2011 FY	208.4 Million TWD	-11.97%
2011 Q4	47.55 Million TWD	-2.88%
2011 Q3	48.96 Million TWD	-8.86%
2010 Q2	52.25 Million TWD	-9.31%
2010 Q1	57.61 Million TWD	0.0%
2010 FY	236.74 Million TWD	27.33%
2010 Q4	73.1 Million TWD	35.96%
2010 Q3	53.77 Million TWD	2.91%
2009 FY	185.92 Million TWD	0.0%

Peer Operating Expenses Comparison of GenMont Biotech Incorporation

Name	Operating Expenses	Operating Expenses Difference
Apex Biotechnology Corp.	389.4 Million TWD	47.559%
Sinphar Pharmaceutical Co.,Ltd.	807.86 Million TWD	74.723%
Panion & Bf Biotech Inc.	817.56 Million TWD	75.023%
Chunghwa Chemical Synthesis & Biotech Co., Ltd.	437.58 Million TWD	53.334%
Abnova (Taiwan) Corporation	126.72 Million TWD	-61.145%
Adimmune Corporation	1.13 Billion TWD	81.988%
Tanvex BioPharma, Inc.	2.16 Billion TWD	90.548%
Polaris Group	-3.06 Million TWD	6762.447%
Energenesis Biomedical CO.,LTD.	267.06 Million TWD	23.537%
UnicoCell Biomed Co., Ltd.	17.89 Million TWD	-1040.996%
PELL Bio-Med Technology Co. Ltd.	385.1 Million TWD	46.975%

Global Stocks Search

GenMont Biotech Incorporation (3164.TW)

Operating Expenses Summary of GenMont Biotech Incorporation

Annual Operating Expenses Chart of GenMont Biotech Incorporation (2023 - 2009)

Historical Annual Operating Expenses of GenMont Biotech Incorporation (2023 - 2009)

Peer Operating Expenses Comparison of GenMont Biotech Incorporation